NCT00553202 · OUTCOME

Overall Survival (OS)

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia · Source last updated 2020-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: At 5 years from HSCT date

What was measured

OS - Time from HSCT until death

Analysis population: Patients without completion of planned therapy (n=68) are excluded from analyses of OS

Groups in this outcome

Treatment (Chemotherapy and Allogeneic SCT)

All Patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Chemotherapy and Allogeneic SCT)	90

Reported measurements

Source class 1

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment (Chemotherapy and Allogeneic SCT)	45.9	Not reported	33.7	57.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
33.7
upper Limit
57.2
value
45.9

denoms

counts
group Id
OG000
value
90
units
Participants

description

OS - Time from HSCT until death

dispersion Type

95% Confidence Interval

groups

description
All Patients
id
OG000
title
Treatment (Chemotherapy and Allogeneic SCT)

param Type

NUMBER

population Description

Patients without completion of planned therapy (n=68) are excluded from analyses of OS

reporting Status

POSTED

time Frame

At 5 years from HSCT date

title

Overall Survival (OS)

type

PRIMARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice